Royalty Pharma Acquires Cypress

Since 1995, Cypress Bioscience has been dedicated to the development of innovative drugs. In 2009, Cypress received FDA approval for Savella® (milnacipran HCl), which is commercialized by Forest Laboratories. Cypress receives a royalty for the sales of Savella. In 2011, Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, acquired Cypress.

For inquiries specific to Cypress, please contact Royalty Pharma.